These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19879995)

  • 1. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis.
    Vélez ID; Gilchrist K; Martínez S; Ramírez-Pineda JR; Ashman JA; Alves FP; Coler RN; Bogatzki LY; Kahn SJ; Beckmann AM; Cowgill KD; Reed SG; Piazza FM
    Vaccine; 2009 Dec; 28(2):329-37. PubMed ID: 19879995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis.
    Chakravarty J; Kumar S; Trivedi S; Rai VK; Singh A; Ashman JA; Laughlin EM; Coler RN; Kahn SJ; Beckmann AM; Cowgill KD; Reed SG; Sundar S; Piazza FM
    Vaccine; 2011 Apr; 29(19):3531-7. PubMed ID: 21414377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.
    Nascimento E; Fernandes DF; Vieira EP; Campos-Neto A; Ashman JA; Alves FP; Coler RN; Bogatzki LY; Kahn SJ; Beckmann AM; Pine SO; Cowgill KD; Reed SG; Piazza FM
    Vaccine; 2010 Sep; 28(40):6581-7. PubMed ID: 20688040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis.
    Llanos-Cuentas A; Calderón W; Cruz M; Ashman JA; Alves FP; Coler RN; Bogatzki LY; Bertholet S; Laughlin EM; Kahn SJ; Beckmann AM; Cowgill KD; Reed SG; Piazza FM
    Vaccine; 2010 Oct; 28(46):7427-35. PubMed ID: 20851080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of copper, selenium and zinc on the response to the Montenegro skin test in subjects vaccinated against American cutaneous leishmaniasis.
    Araújo AP; Rocha OG; Mayrink W; Machado-Coelho GL
    Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):64-9. PubMed ID: 17980395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.
    Coler RN; Goto Y; Bogatzki L; Raman V; Reed SG
    Infect Immun; 2007 Sep; 75(9):4648-54. PubMed ID: 17606603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.
    Vélez ID; Gilchrist K; Arbelaez MP; Rojas CA; Puerta JA; Antunes CM; Zicker F; Modabber F
    Trans R Soc Trop Med Hyg; 2005 Aug; 99(8):593-8. PubMed ID: 15893351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
    Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant.
    Skeiky YA; Coler RN; Brannon M; Stromberg E; Greeson K; Crane RT; Webb JR; Campos-Neto A; Reed SG
    Vaccine; 2002 Sep; 20(27-28):3292-303. PubMed ID: 12213399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
    Musa AM; Khalil EA; Mahgoub FA; Elgawi SH; Modabber F; Elkadaru AE; Aboud MH; Noazin S; Ghalib HW; El-Hassan AM;
    Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized subunit vaccine protects against experimental leishmaniasis.
    Bertholet S; Goto Y; Carter L; Bhatia A; Howard RF; Carter D; Coler RN; Vedvick TS; Reed SG
    Vaccine; 2009 Nov; 27(50):7036-45. PubMed ID: 19786136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
    Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
    Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
    Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.
    Sharifi I; FeKri AR; Aflatonian MR; Khamesipour A; Nadim A; Mousavi MR; Momeni AZ; Dowlati Y; Godal T; Zicker F; Smith PG; Modabber F
    Lancet; 1998 May; 351(9115):1540-3. PubMed ID: 10326536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and perspectives of the immunotherapy of leishmaniasis.
    El-On J
    Isr Med Assoc J; 2009 Oct; 11(10):623-8. PubMed ID: 20077951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine.
    Botelho AC; Mayrink W; Oliveira RC
    Acta Trop; 2009 Nov; 112(2):143-8. PubMed ID: 19631187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.